The RADprecise collaborative project aims to personalize radiotherapy treatment for cancer patients. We plan to improve the prediction of the risk for side effects after radiotherapy using multiple biomarkers from blood and tissue in addition to clinical and personal factors. Information from the prediction models will be incorporated into radiotherapy treatment planning systems. With this “biologically extended treatment planning system”, radiotherapy can be adapted to each individual patient’s sensitivity to radiation to minimize side effects while still effectively eliminate the tumour. This shall provide more effective treatment and benefits for the patient such as improving quality of life.
We will use data from a large established cohort of breast and prostate cancer patients from the REQUITE project (www.requite.eu). Follow-up of patients in Germany, Italy, Spain and the UK will be extended to determine long-term side effects up to five years. New biomarkers from blood and tissue will be tested, including a cell-based assay and gene-expression. Scientists as well as two companies in France together with patient advocates will collaborate in this project to take biological optimisation into the clinic.
